health biotech news today obesity drugs glp-1 Novartis, Alector, Merck, Alnylm, UniQure : Readout Newsletter Chart: 1 in 8 Americans

Epub 2021 May 19

Fridays: Fridays delivers a holistic GLP-1 program that combines lifestyle coaching, therapeutic support, and a dedicated insurance concierge under one all-inclusive program fee

[DOI] [PMC free article] [PubMed] [Google Scholar] 31.Hjerpsted JB, Flint A, Brooks A, et al

R.Steinberg, Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression, Diabetes, Obesity and Metabolism (2026): 115, #MASLD #MASH #LiverHealth #MetabolicHealth #GLP1 #Obesity #Diabetes #Hepatology To view or add a comment, sign in Here the authors propose therapeutic advancement of the adipokine Adissp, an adipokine without a known receptor, that promotes an insulin-independent mechanism for glucose uptake and augments thermogenesis, representing a promising class of therapeutics for concurrently and synergistically treating insulin resistance, diabetes, obesity, and associated comorbidities

Psychological aspects of switching receive less attention than physical effects but significantly impact experiences

Both GLP-1 agonists and Actos slow the decline of insulin production, which is a key reason for rising blood sugar levels over time, leading many with type 2 diabetes to start insulin therapy